J Cancer 2016; 7(15):2266-2269. doi:10.7150/jca.15921 This issue

Research Paper

New panel of microsatellite alterations detectable in the EBC for lung cancer prognosis

Giovanna E Carpagnano, Donato Lacedonia, Elisabetta Crisetti, Domenico Martinelli, Maria P Foschino-Barbaro

Institute of Respiratory Diseases, Department of Medical and Surgical Sciences, University of Foggia, Italy.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Carpagnano GE, Lacedonia D, Crisetti E, Martinelli D, Foschino-Barbaro MP. New panel of microsatellite alterations detectable in the EBC for lung cancer prognosis. J Cancer 2016; 7(15):2266-2269. doi:10.7150/jca.15921. Available from https://www.jcancer.org/v07p2266.htm

File import instruction


Our research group demonstrated, in a precedent study, the prognostic power of the 3p microsatellites alterations (MAs) detectable in exhaled breath condensate (EBC) in NSCLC patients. The analysis of genetic markers in the EBC might have precious clinical and economic consequences when inserted in diagnostic and follow up programs for lung cancer.

The aim of this study was to evaluate the prognostic value of a new panel of MAs in the EBC of patients with NSCLC.

We enrolled 45 NSCLC patients during a period of 36 months and the follow-up period was 156 weeks. We analyzed MAs for eight markers in EBC samples: D3S2338, D3S1266, D3S1300, D3S1304, D3S1289, D5S2094, D3S1313, and AFMa305ye1.

Our study showed that the presence of more than 2 simultaneous MAs reduces outcome in NSCLC patients. The new panel of eight microsatellites markers proposed in EBC samples could have a potential clinical role in assessing survival in lung cancer patients.

Keywords: lung cancer, exhaled breath condensate, microsatellite, prognosis.